Welcome to our dedicated page for Taysha Gene Therapies SEC filings (Ticker: TSHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Taysha Gene Therapies, Inc. (Nasdaq: TSHA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company developing AAV-based gene therapies for severe monogenic CNS diseases, Taysha uses these filings to report on its financial condition, capital-raising activities and material developments in its TSHA-102 Rett syndrome program.
Here, users can review Form 8-K current reports in which Taysha describes material events such as amendments to its at-the-market Sales Agreement for common stock, public follow-on offerings, and key press releases. Recent 8-K filings have incorporated announcements on FDA Breakthrough Therapy designation for TSHA-102, alignment on the REVEAL pivotal trial protocol and statistical analysis plan, and the company’s regaining of full rights to its lead TSHA-102 program.
Investors can also use this page to locate references to quarterly and annual financial results, which are furnished as exhibits to 8-K filings, and to understand how Taysha is funding BLA-enabling manufacturing, REVEAL and ASPIRE clinical trial activities, and general corporate operations. The filings identify TSHA as a Nasdaq-listed issuer with common stock registered under Section 12(b) of the Exchange Act and outline the structure of its equity offering programs.
Stock Titan enhances these regulatory documents with AI-powered summaries that explain the key points of lengthy filings in clear language. Users can quickly see what each 8-K covers, track changes to capital programs and material agreements, and follow how clinical and regulatory milestones for TSHA-102 are reflected in Taysha’s official SEC record. Real-time updates from EDGAR, along with structured views of exhibits and items, help readers navigate the company’s filing history efficiently.
Taysha Gene Therapies, Inc. is asking stockholders to vote at its June 1, 2026 virtual annual meeting on four items: electing two directors, ratifying Deloitte & Touche LLP as auditor, approving executive pay on an advisory basis, and choosing how often to hold future say‑on‑pay votes.
The record date is April 8, 2026, with 287,341,999 common shares entitled to one vote each and a majority of shares required for quorum. The board highlights its mix of independent and management directors, committee structure, insider‑trading and hedging policies, and detailed 2025 executive pay, equity awards, and potential severance on termination or change in control.
Taysha Gene Therapies, Inc. President and Head of R&D Nagendran Sukumar exercised employee stock options for 19,021 shares of common stock at an exercise price of $1.71 per share and sold 200,000 common shares at a weighted average price of $4.46 per share. The sale occurred in multiple trades between $4.335 and $4.625 and was made pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2025. Following these transactions, he directly holds 1,136,410 shares of common stock and 455,920 stock options.
Taysha Gene Therapies filed a Form 144 reporting a proposed sale of 200,000 shares by Sukumar Nagendran. The filing lists a sale date of 01/12/2026 and a gross amount of $942,740 tied to those shares. The disclosure also lists prior grants: 131,550 RSUs, 49,429 RSUs, and 19,021 stock options with grant dates shown in 2024 and 2025.
Taysha Gene Therapies is a clinical-stage biotech focused on AAV9 gene therapies for severe central nervous system diseases, led by TSHA-102 for Rett syndrome. The company is running REVEAL and ASPIRE trials to support a potential broad label in patients aged 2 years and older.
In Part A of the REVEAL Phase 1/2 trials, 12 females aged 6‑21 years received TSHA-102, with 10 evaluable patients showing 22 developmental milestones gained or regained and 165 additional functional skills and improvements across communication, fine motor, gross motor and autonomic function. An 83% response rate at six months was observed in the high-dose cohort, with clinically meaningful R-MBA and CGI-I improvements and no treatment-related serious adverse events or dose-limiting toxicities as of March 2026.
The pivotal single-arm REVEAL Part B trial will enroll 15 females aged 6 to <22 years at the high dose (1x10^15 total vg), using milestone gain/regain as the primary endpoint with a 6‑month interim analysis that may support a biologics license application. The ASPIRE study in 2 to <4‑year‑olds will provide safety data for label expansion. TSHA-102 has multiple regulatory designations, including orphan drug, rare pediatric disease, Fast Track, RMAT, Breakthrough Therapy and U.K. ILAP, and Taysha is aligning Chemistry, Manufacturing and Controls and PPQ campaigns to enable a planned BLA. The company also discloses earlier-stage programs TSHA-113 for tauopathies and TSHA-114 for Fragile X syndrome, and outlines its licensing and intellectual property framework.
Taysha Gene Therapies reported full-year 2025 results and a major update on its Rett syndrome program TSHA-102. Revenue was $9.8M versus $8.3M in 2024, while research and development expenses rose to $86.4M and general and administrative expenses to $33.9M.
The company recorded a net loss of $109.0M, or $0.34 per share, compared with a $89.3M loss, or $0.36 per share, a year earlier. Cash and cash equivalents were $319.8M as of December 31, 2025, and management expects current cash resources to fund operations into 2028.
Clinically, multiple Rett syndrome patients have been dosed in the REVEAL pivotal trial of TSHA-102, with dosing in the REVEAL and ASPIRE trials expected to complete in Q2 2026. The therapy has shown a favorable tolerability profile to March 2026, and Taysha reached written FDA alignment on its commercial manufacturing and comparability strategy to support a planned BLA submission.
Taysha Gene Therapies reporting person submitted a Form 144 relating to Common Stock sales tied to an RSU award that vested and was settled in stock on 02/27/2026, where consideration was the reporting person’s continued service.
The filing lists prior sales during the past three months: 23,533 shares on 01/23/2026 for $111,781.75, 7,107 shares on 01/26/2026 for $32,763.27, and 697 shares on 02/04/2026 for $3,150.44.
Vestal Point Capital, LP and Ryan Wilder reported passive ownership of 13,750,000 shares of Taysha Gene Therapies, Inc. common stock, equal to 5% of the class. The stake is held through a fund and a managed account advised by Vestal Point Capital.
The ownership percentage is based on 273,915,373 shares of common stock outstanding as of November 4, 2025, as disclosed in Taysha’s Form 10-Q for the quarter ended September 30, 2025. The filers state the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the company.
RTW Investments, LP and Managing Partner Roderick Wong report beneficial ownership of Taysha Gene Therapies common stock. They are deemed to beneficially own 23,407,133 shares, representing 8.3% of the common stock, including warrants exercisable for 7,008,836 shares, based on 273,919,373 shares outstanding as of November 4, 2025.
The shares are held by RTW-managed funds, which have the right to receive dividends and sale proceeds. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Taysha Gene Therapies.
Taysha Gene Therapies Chief Financial Officer Kamran Alam reported a small insider sale tied to taxes. On February 4, 2026, he sold 1,655 shares of common stock at $4.52 per share. The footnote explains this was a mandatory sell-to-cover transaction to pay income taxes from restricted stock unit vesting. After the sale, Alam directly held 1,442,131 shares of Taysha Gene Therapies common stock.